About N-sulphoglucosamine sulphohydrolase
N-sulphoglucosamine sulphohydrolase (SGSH) is a protein
from Homo sapiens identified by UniProt accession
P51688, 502 residues long.
MolForge cross-references it against 0 known binders and
72 disease associations.
Target properties
| Protein name | N-sulphoglucosamine sulphohydrolase |
| UniProt accession | P51688 |
| Gene | SGSH |
| Organism | Homo sapiens |
| Length | 502 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (72)
Diseases linked to this target (Open Targets).
- mucopolysaccharidosis type 3A · score 0.87
- mucopolysaccharidosis type 3 · score 0.70
- genetic disorder · score 0.53
- Retinal dystrophy · score 0.51
- Developmental regression · score 0.42
- Gastrointestinal dysmotility · score 0.42
- Nystagmus · score 0.42
- Diarrhea · score 0.42
- Global developmental delay · score 0.42
- Neurodegeneration · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P51688-F1 | alphafold | PREDICTED | 96.36 | — |
Amino-acid sequence (502 residues)
MSCPVPACCA LLLVLGLCRA RPRNALLLLA DDGGFESGAY NNSAIATPHL DALARRSLLF RNAFTSVSSC SPSRASLLTG LPQHQNGMYG LHQDVHHFNS FDKVRSLPLL LSQAGVRTGI IGKKHVGPET VYPFDFAYTE ENGSVLQVGR NITRIKLLVR KFLQTQDDRP FFLYVAFHDP HRCGHSQPQY GTFCEKFGNG ESGMGRIPDW TPQAYDPLDV LVPYFVPNTP AARADLAAQY TTVGRMDQGV GLVLQELRDA GVLNDTLVIF TSDNGIPFPS GRTNLYWPGT AEPLLVSSPE HPKRWGQVSE AYVSLLDLTP TILDWFSIPY PSYAIFGSKT IHLTGRSLLP ALEAEPLWAT VFGSQSHHEV TMSYPMRSVQ HRHFRLVHNL NFKMPFPIDQ DFYVSPTFQD LLNRTTAGQP TGWYKDLRHY YYRARWELYD RSRDPHETQN LATDPRFAQL LEMLRDQLAK WQWETHDPWV CAPDGVLEEK LSPQCQPLHN EL
Explore N-sulphoglucosamine sulphohydrolase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets